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Abstract
Background: The most common approach used in generating cell lines for the production of therapetic proteins
relies on gene amplification induced by a drug resistance gene e. g., DHFR and glutamine synthetase. Practically,
this results in screening large number of clones for the one that expresses high levels of the biologic in a stable
manner. The inefficiency of mammalian vector systems to express proteins in a stable manner typically involves
silencing of the exogenous gene resulting from modifications such as methylation of CpG DNA sequences, histone
deacetylation and chromatin condensation. The use of un-methylated CpG island fragments from housekeeping
genes referred to as UCOE (ubiquitous chromatin opening elements) in plasmid vectors is now well established for
increased stability of transgene expression. However, few UCOE-promoter combinations have been studied to date
and in this report we have tested 14 different combinations.
Findings: In this report we describe studies with two different UCOEs (the 1.5 Kb human RNP fragment and the
3.2 Kb mouse RPS3 fragment) in combination with various promoters to express a large protein (B domain deleted
factor VIII; BDD-FVIII) in a production cell line, BHK21. We show here that there are differences in expression of
BDD-FVIII by the different UCOE-promoter combinations in both attached and serum free suspension adapted cells.
In all cases, the 1.5 Kb human RNP UCOE performed better in expressing BDD-FVIII than their corresponding 3.2 Kb
mouse RPS3 UCOE. Surprisingly, in certain scenarios described here, expression from a number of promoters was
equivalent or higher than the commonly used and industry standard human CMV promoter.
Conclusion: This study indicates that certain UCOE-promoter combinations are better than others in expressing
the BDD-FVIII protein in a stable manner in BHK21 cells. An empirical study such as this is required to determine
the best combination of UCOE-promoter in a vector for a particular production cell line.
Findings
Introduction
The production of a protein therapeutic depends on a
number of different factors including expression, stabi-
lity of the cell line, post translational modifications, pro-
tein trafficking, secretion and viability of cells when
grown to high density in a bioreactor. The first step in
creating a production cell line is the transfection of an
expression vector that encodes the biologic. Levels of
RNA expression depend on the expression vector used.
Numerous commercially available mammalian expres-
sion vectors are available that utilize different regulatory
elements to maximize the expression of the therapeutic
protein including promoters and enhancers, post-tran-
scriptional elements such as WPRE and sequences that
control the termination of transcription. Besides the
levels of protein expressed, achieving reliable and stable
transgene expression in mammalian cells is another
major challenge. The inefficiency of mammalian vector
systems to express proteins in a stable manner typically
involves silencing of the exogenous gene that results
from modification of the integrated vector or its vicinity,
such as methylation of CpG DNA sequences, histone
deacetylation and chromatin condensation [1-3]. Most
conventional vectors suffer from position effects and
chromatin shut down thus resulting in gene silencing
over time. Chromatin position effects makes the
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tein therapeutic a difficult, time consuming and expen-
sive process. The most commonly used approach used
in the generation of such cell lines relies on gene ampli-
fication induced by a combination of a drug resistance
gene e. g., DHFR and glutamine synthetase [4,5] and
stringent selective pressure. The DHFR and glutamine
synthetase (GS) genes are mainly used for selection in
CHO and NSO cells, respectively. In both cases, the
selection occurs in the absence of appropriate metabo-
lite (s): glycine, hypoxanthine, and thymidine for DHFR
and glutamine for GS. Both these markers have the
advantage of supporting amplification of the copy num-
ber of the integrated DNA by exposure of selected cells
to increasing amounts of methotrexate (MTX) or
methionine sulphoximine (MSX), respectively [6]. Practi-
cally, this would result in screening a large number of
clones for the one that expresses high levels of the bio-
logic in a stable manner. There have been recent studies
that have addressed the critical issue of stable expres-
sion. As an example, the inclusion of MAR (matrix asso-
ciated regions) in the vector system has been exploited
to increase the stability of expression of a number of
exogenous genes in mammalian cells [7-10]. In addition,
the discovery that certain un-methylated CpG sequences
of housekeeping genes known as UCOE (ubiquitous chro-
matin opening elements) confers resistance to heterochro-
matin-mediated silencing has led to the incorporation of
these elements into expression vectors including lentiviral
vectors [11-13]. The addition of the UCOE in the expres-
sion vector is thought to create a transcriptionally active,
open chromatin environment around an integrated trans-
gene, maximizing its potential to be transcribed into pro-
t e i na n dt h i se f f e c ti si r r e s p ective of the position of the
transgene in the chromosome. The UCOE expression
technology therefore provides major improvements in
gene expression in stably-transfected mammalian cells
through effects on the structure of chromatin (irrespective
of chromosomal integration site) which results in the pre-
vention of transgene silencing and gives consistent, stable
and high-level gene expression. Therefore, by nature of
the inherent properties of UCOE, the screening for cell
lines that express high amounts of the biologic is less
labor, time and cost intensive than other methods. Also,
the chance of selecting a clone that is highly stable is bet-
ter with plasmid vectors containing the UCOE.
There have been previous reports that large fragment
containing the CpG islands from the human
HNRPA2B1 and TBP-PSNB1 loci (designated RNP and
TBP) are resistant to heterochromatin mediated silen-
cing of endogenous genes transcribed from promoters
associated with these genes [14]. The RNP UCOE is
derived from and consists of the dual divergently tran-
scribed promoter region of the HNRPA2B1-CBX3
genes, whereas the RPS3 UCOE consists of a single pro-
moter element [15].
Also, a strong promoter, namely the human CMV
promoter (hCMV) that is preceded by a large portion of
the RNP CpG island (8 Kb) confers major benefits in
transgene expression from this promoter when incorpo-
rated in a plasmid vector [16]. Reducing the CpG island
fragment of the RNP locus to 1.5 Kb still conferred the
benefits of expression and stability [16].
As far as we know, this is the first extensive study
comparing different promoter-UCOE combinations has
been undertaken. In this study, the 1.5 Kb RNP UCOE
was compared to the 3.2 Kb mouse ribosomal protein
S3 (RPS3) gene locus UCOE in the context of a number
of different promoters including hCMV to express the
transgene BDD-FVIII (B-domain deleted factor VIII) in
the production line BHK21.
Comparison of the different UCOE-promoter combinations
in adherent BHK21 cells
An earlier study compared different lengths of the
human RNP CpG fragments in a vector system in the
context of a strong promoter, hCMV (14). In that study,
three different CpG fragment sizes were analyzed: 8.0
Kb, 4.0 Kb and 1.5 Kb. The 1.5 Kb fragment was able to
confer stable high expression levels of transgene expres-
sion. Here, we constructed 7 different 1.5 Kb UCOE
promoter combinations, and 7 different 3.2 Kb UCOE
promoter combinations including the 1.5 Kb RNP
UCOE with the hCMV promoter to drive the expression
of BDD-FVIII in the production cell line BHK21.
Fourteen constructs (Figure 1) were transiently trans-
fected, and secreted BDD-FVIII was measured at the activ-
ity (Figure 2A) and the protein level (Figure 2B). As shown
in Figure 2, there were many promoters that efficiently
expressed active BDD-FVIII and were equal to or better
than the hCMV promoter. Ubc and mouse CMV
(mCMV) promoter driven expression was significantly
higher than hCMV (with the 1.5 or 3.2 Kb UCOE, about
1.4-8 folds higher, P < 0.01 in activity and 1.1-25 folds
higher in secreted protein levels, P < 0.05). Surprisingly,
the expression levels driven by most promoters, except
hCMV and MPSV promoters, were significantly greater
than the guinea pig CMV (gCMV) promoter (with the 1.5
or 3.2 Kb UCOE, about 1.7-4 folds higher, P < 0.01 in
activity and 1.6-4.5 folds higher, p < 0.01 in secreted pro-
tein levels). The general trend in BDD-FVIII activity/ml
was comparable to the levels of protein secreted into the
media and as measured by ELISA. In all cases, the 1.5 Kb
human RNP UCOE-promoter combinations were better
than the 3.2 Kb mouse RPS3 UCOE promoter combina-
tions, suggesting the influence of the UCOE sequence on
expression of the transgene (Figure 2). These UCOE-pro-
moter combinations behaved differently in other cell lines
tested; 293T, CHOK1 and HKB11 (data not shown).
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BDD-FVIII in adherent BHK21 cells in transient trans-
fection experiments were taken forward to create stable
cell lines and compared with the gCMV promoter (in
combination with both the 1.5 Kb human RNP and the
3.2 Kb mouse RPS3 UCOEs). One month post transfec-
tion, BDD-FVIII mRNA, secreted protein, and secreted
activity levels were measured (Figure 3A-C). As with the
transient transfection studies the 1.5 Kb UCOE always
performed better than the 3.2 Kb UCOE to express
BDD-FVIII (Figure 3A-C). The FVlll-BDD RNA,
secreted protein and FVlll activity were increased about
1.27-4.5, 1.35-5.5 and 1.76-5.88 folds, respectively, with
all of the tested promoters (P < 0.05-0.001). This indi-
cates that the 1.5 Kb UCOE is a better choice of the
two UCOE fragments evaluated in this study for maxi-
mal stable expression of BDD-FVIII in BHK21 cells. The
1.5 Kb human RNP in combination with the human
ubiquitin promoter performed significantly better than
the other UCOE-promoter combinations tested (Figure
3A-C); it showed over 40 fold higher expression of
BDD-FVIII when compared to the 1.5 Kb RNP - gCMV
promoter combination. To test whether this was an arti-
fact caused as a result of differences in copies of inte-
grated plasmids, a relative copy number determination
was performed. Figure 3D demonstrates that the high
levels of production and secretion of BDD-FVIII by the
cell line transfected with the 1.5 Kb RNP-UCOE Ubiqui-
tin promoter is not due to an unusually high number of
integrated copies of that plasmid.
Comparison of the different UCOE-promoter combinations
in serum free suspension adapted BHK21 cells
BHK21 cells were adapted to suspension culture by
serum weaning so that they could be maintained in a
Drug R UCOE promoter
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Figure 1 Schematic representation of all the plasmid vectors constructed and used in the studies.
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Page 3 of 8serum free environment. The main advantage of grow-
ing these cells in serum free media is that the produc-
tion cells are not in contact with animal proteins, and
that would help purify the secreted therapeutic protein
w i t h o u ta n ys e r u mp r o t e i n“contaminant”.E v e ns m a l l
levels of serum protein in the purified product will likely
increase the chance of an immune response to the bio-
logic in patients receiving treatment. The cells that were
derived by the adaptation of BHK21 cells to suspension
grew to a density of 4.6 × 10
6/ml, were over 93% viable
and had a doubling time of 20 hours in serum free
media. The transfection of suspension adapted BHK21
cells in serum free media has traditionally been ineffi-
cient. Therefore in the past, to create a BHK21 produc-
tion cell line required first the transfection of adherent
cells, followed by generating stable lines as adherent cul-
tures and then adapting these to serum free suspension
culture. The advantage of transfecting serum free cells
grown in suspension culture can not be underestimated
as it saves time, effort and resources that ultimately
results in reduced cost of goods.
The data from transient transfection studies in serum
free suspension adapted BHK21 cells using the same
set of UCOE-promoter combinations as in the adher-
ent studies are shown in Figure 4. Again as with
adherent BHK21 cell studies, here too in all cases
the1.5 Kb human RNP fragment- promoter combina-
tions performed better in expressing the transgene
when compared with the corresponding 3.2 Kb RSP3
mouse UCOE - promoter combinations. The expres-
sion levels increased 1.3-15.5 folds in activity and 1.2-
25.5 folds in secreted protein with the tested promo-
ters (P < 0.05-0.01, except gCMV). All the 1.5 Kb
human RNP fragment - promoter combinations, except
the gCMV, the MPSV promoters were equal to, or bet-
ter expressers of BDD-FVIII than the 1.5 Kb human
RNP-hCMV promoter combination (the expression
levels driven by SRa,U b ca n dm C M Vw e r e1 . 3 - 1 5 . 7
folds higher in activities and 1.4-31 folds higher in
secreted protein, Figure 4), As expected, the COAT-
EST data that measures the activity of the secreted
BDD-FVIII in the media (Figure 4A) correlated very
well with the actual amount of protein in the media
(Figure 4B). Due to the obvious superior expression
from the 1.5 Kb human RNP constructs in both the
adherent and suspension culture settings, all further
studies were carried out only with the 1.5 Kb human
RNP constructs. One month of culture under selective
pressure with hygromycin was performed as with
adherent culture. As was the case in adherent cell stu-
dies, there was a strong correlation between BDD-
FVIII mRNA expression (Figure 4C, except in the case
of the SRa and the rCMV promoters), secreted activity
(Figure 4D) and secreted protein levels (as measured
by both ELISA and western blot, Figures 4E and 4F,
respectively). The surprising finding in this study was
that the mCMV promoter driven expression had sig-
nificantly dropped compared to what would be
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Figure 2 Transient transfection studies in adherent BHK21 cells comparing the different UCOE plasmids. Adherent BHK21 cells were
transfected with equimolar amounts of the UCOE plasmids listed in figure 1 and the FVIII activity/ml (A), and the BDD protein levels secreted as
measured by ELISA (B) were measured. Data was statistically analyzed using ‘t’ test to detect significant differences between the 3.2 Kb and the
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Page 4 of 8expected from transient expression studies, as also
seen with the adherent stable cells. The integrated
copy number studies suggest that this may partly be
due to reduced integration of the plasmid (Figure 5B).
T h es a m er e a s o n i n gc o u l da l s ob eu s e df o rl o w e r
expression from the gCMV promoter in suspension
cultured stable cells. Another deviation from what
would be expected from transient expression studies
was the high BDD-FVIII expression levels driven from
the MPSV promoter; this promoter generated low
levels of expression similar to the gCMV promoter in
the transient transfection studies. The SRa,t h eU b c
and the rCMV promoter behaved as expected. The
unusually high levels of expression and activity (> 40
fold higher than the gCMV promoter) seen from the
Ubc promoter containing stable adherent cells was not
seen in the suspension adapted cells.
Stability of the UCOE promoter derived cell lines
Serum free suspension BHK21 cells from the 1.5 Kb
human RNP-promoter combinations were cultured for a
period of two months to study the stability of these
pooled populations. Activity (Figure 5A) and relative
DNA copies (Figure 5B) were measured at one and two
months post transfection. There was no significant dif-
ference in activity in most cases, except that there was a
reduction in the case of the mCMV and SRa promoter
based cell line and a slight increase in activity in the
case of the MPSV promoter (Figure 5A). The reduction
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Figure 3 Stable pooled adherent BHK21 studies. Adherent BHK21 cells were transfected with different plasmids, cultured under hygromycin
selection for one month and the levels of BDD mRNA (A), secreted protein (B) and secreted activity (C) were measured. The relative copies of
integrated BDD cDNA was measured by qPCR (D). Data was statistically analyzed using ‘t’ test to detect significant differences between the 3.2
Kb and the 1.5 Kb UCOE containing expression constructs (*: p < 0.05 or more).
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Page 5 of 8in activity in SRa promoter cell line may be attributed
to the reduction in relative DNA integrated copies, and
the reduction in the mCMV promoter cell line seems
not to be due to a reduction in copy number, but due
to some post integration phenomenon (Figure 5B).
Recently it has been shown that the ability of UCOE to
confer stability of expression on a linked promoter is
due at least in part to it being able to negate DNA-
methylation mediated silencing [13,15], and this may
contribute towards the observed stability in most of the
UCOE-promoter combinations tested but not all (loss of
stability in the case of mCMV and SRa).
Conclusion
The 1.5 Kb human RNP CpG fragment has previously
been shown to confer higher expression and stability of
the transgene in production cells when placed ahead of
the hCMV promoter. We investigated two UCOE frag-
ments, the 1.5 Kb human RNP CpG fragment and the
3.2 Kb mouse RPS3 fragment. These UCOE fragments
were placed upstream of seven different commonly used
promoters to generate 14 different plasmid vectors that
encode the FVIII-BDD cDNA to study the effect of the
UCOE sequence and the combination of the different
promoters to express FVIII-BDD in BHK21 cells.
We observed that in combination with the different
promoters, the corresponding 1.5 Kb UCOE is better
than the 3.2 Kb UCOE at expressing FVIII-BDD in both
attached and serum free suspension adapted BHK21
cells. The differential integration of the 1.5 Kb UCOE
and the 3.2 Kb UCOE plasmids can not be attributed to
this as the relative copy numbers of integrated plasmids
in pooled populations of established cells were not suffi-
ciently different to explain the differences in expression
b yt h et w oU C O E s .T h ed u a ld i v e r g e n t l yt r a n s c r i b e d
promoter of the HNRPA2B1-CBX3 genes may contri-
bute towards this phenomenon. Based on this, we con-
clude that the 1.5 Kb RNP fragment is a better choice
for the expression of the FVIII-BDD transgene in
BHK21 cells.
From transient transfection studies we conclude that
in both adherent and suspension adapted BHK21 cells,
all the promoters were better than the gCMV promo-
ter, except the hCMV promoter in the context of the
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Page 6 of 81.5 Kb UCOE is better than the corresponding gCMV
promoter. The similarities in the expression trends
between suspension adapted and adherent BHK21 cells
suggests that the transcriptional machinery is similar
in the two morphologically different cell types that
were derived from the same parental BHK21 cells.
However, we observed differences in expression level
trends when these plasmids were transfected into other
cell types.
When the transfected cells were cultured for over a
month, there were many unexpected observations. In
the case of adherent cells, there was a substantial loss of
expression from the mCMV and the SRa promoters
when compared to the gCMV promoter and the Ubc
promoter based expression seemed to increase relative
to the gCMV promoter. These changes were not due to
large differences in copy numbers. The decrease in
expression levels may be explained by DNA methylation
mediated gene silencing over time. It is however difficult
to explain the increased expression by the Ubc promo-
ter. Suspension adapted cells grown for a month showed
differences in gene expression levels, but these may be a
result of differences in gene copy numbers. These cells
are stable as the activity levels nor the gene copies chan-
ged after an additional month of continuous culture
under selection. There was no silencing observed. The
only significant change was decreased expression from
the SRa promoter and that can be explained as a result
of decreased number of integrated copies that may be a
result of shift in population pools.
We conclude that an empirical study such as this is
necessary to evaluate the expression vector system for a
given production cell line. Also, optimizing conditions
f o rt r a n s f e c t i o ni ns u s p e n s i o na d a p t e ds e r u mf r e e
BHK21 cells can be achieved and is beneficial in not
only saving time and resources, but also in the purifica-
tion of the biologic with fewer protein contaminants
resulting in reduced immunogenicity.
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